Get the Stockscreener App
12.94
1.15%
-0.15
After Hours:
12.90
-0.04
-0.31%
CorMedix Inc stock is traded at $12.94, with a volume of 1.69M.
It is down -1.15% in the last 24 hours and up +12.52% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$13.09
Open:
$13.09
24h Volume:
1.69M
Relative Volume:
0.54
Market Cap:
$965.96M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-14.07
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
+4.35%
1M Performance:
+12.52%
6M Performance:
+17.96%
1Y Performance:
+88.63%
1-Day Range:
$12.81
$13.30
1-Week Range:
$11.58
$13.83
52-Week Range:
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
12.94 | 954.76M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
Cormedix CEO Todisco sells $650,000 in shares - Investing.com
CorMedix Inc. Stock (CRMD) Opinions on Recent Analyst Rating Upgrade - Quiver Quantitative
Cormedix COO Hurlburt sells $711k in shares By Investing.com - Investing.com Canada
Cormedix COO Hurlburt sells $711k in shares - Investing.com
Zelnick Kaufman, chief legal officer at CorMedix, sells $670k in shares - Investing.com
Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT - MSN
CorMedix Completes Acquisition of Melinta Therapeutics - MSN
CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com
CorMedix makes $5M minority equity investment in Talphera - MSN
CorMedix stock investment in Talphera adds pipeline optionality, JMP reiterates By Investing.com - Investing.com
Talphera Announces $29 Mln Private Placement Led By CorMedix And Institutional Investors - Nasdaq
Order Flow Trends Show Accumulation in CorMedix Inc.July 2025 Movers & Weekly Breakout Stock Alerts - beatles.ru
Will CorMedix Inc. stock hit new highs in YEARMarket Sentiment Review & Reliable Momentum Entry Alerts - 뉴스영
Talphera Secures Up To $29 Mln In Private Placement Led By CorMedix - Nasdaq
Short Term Charts Align With Long Term Uptrend in CorMedix Inc.Weekly Trading Summary & Free Safe Capital Growth Stock Tips - beatles.ru
What makes CorMedix Inc. stock attractive todayJuly 2025 Selloffs & Safe Capital Growth Trade Ideas - beatles.ru
Should you buy the dip on CorMedix Inc.2025 Market Outlook & Stepwise Entry/Exit Trade Alerts - beatles.ru
CorMedix leads $29 million financing round in Talphera By Investing.com - Investing.com Canada
CorMedix leads $29 million financing round in Talphera - Investing.com
CorMedix Backs Talphera With $5 Million Investment And Board Seat - Finimize
CorMedix Invests $5 Million in Talphera - MarketScreener
CorMedix Inc. Makes $5 Million Strategic Investment in Talphera, Inc. to Support Development of Niyad™ - Quiver Quantitative
CorMedix announces strategic minority investment in Talphera - MarketScreener
$5M Strategic Investment: CorMedix Secures First Rights to Acquire Talphera's Breakthrough CRRT Drug - Stock Titan
CorMedix : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - MarketScreener
Is CorMedix Inc. stock a smart retirement pickExit Point & Free Real-Time Market Sentiment Alerts - beatles.ru
Talphera, Inc. announced that it expects to receive $29 million in funding from CorMedix Inc., Nantahala Capital Management, LLC, Rosalind Advisors, Inc. and other investors - MarketScreener
Can CorMedix Inc. withstand a market correctionEntry Point & Daily Profit Maximizing Trade Tips - classian.co.kr
Is CorMedix Inc. backed by strong institutional buyingProduct Launch & Entry Point Confirmation Signals - خودرو بانک
When is the best time to exit CorMedix Inc.Weekly Trade Summary & Technical Pattern Based Signals - Newser
CorMedix at Cantor Global Healthcare Conference: Strategic Growth and Diversification - Investing.com Australia
Will CorMedix Inc. benefit from current market trendsWeekly Stock Report & AI Optimized Trading Strategy Guides - خودرو بانک
Using RSI to spot recovery in CorMedix Inc.July 2025 WrapUp & Weekly Watchlist of Top Performers - Newser
Real time pattern detection on CorMedix Inc. stock2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - Newser
Can trapped investors hope for a rebound in CorMedix Inc.July 2025 WrapUp & Verified Chart Pattern Signals - Newser
Comparing CorMedix Inc. in custom built stock radars2025 Bull vs Bear & Short-Term Trading Alerts - Newser
Deerfield Management Sells Melinta Therapeutics To CorMedix - citybiz
Is CorMedix Inc. showing signs of accumulationJuly 2025 Outlook & Stock Portfolio Risk Management - Newser
Cormedix Inc. shares fall 1.05% premarket after presenting at Cantor and Morgan Stanley conferences. - AInvest
How high can CorMedix Inc. stock goJuly 2025 Recap & Expert Curated Trade Ideas - Newser
What the charts say about CorMedix Inc. todayWeekly Trend Recap & Daily Profit Maximizing Trade Tips - Newser
Cormedix (CRMD) Gets a Buy from Truist Financial - The Globe and Mail
CorMedix to Participate in Upcoming Investor Conferences - 富途牛牛
Sentiment analysis tools applied to CorMedix Inc.2025 Dividend Review & Free Community Consensus Stock Picks - Newser
Statistical indicators supporting CorMedix Inc.’s strengthProduct Launch & Comprehensive Market Scan Reports - Newser
Institutional Confidence Rises as CorMedix Inc. (CRMD) Hits Profitability - MSN
Analyzing CorMedix Inc. with multi timeframe charts2025 Key Highlights & Entry Point Confirmation Alerts - Newser
CorMedix Inc.’s volatility index tracking explainedBull Run & Free Long-Term Investment Growth Plans - Newser
Published on: 2025-09-04 02:05:07 - Newser
Will CorMedix Inc. benefit from AI trends2025 Sector Review & Momentum Based Trading Signals - خودرو بانک
CorMedix completes $300M acquisition of Melinta Therapeutics - NJBIZ
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):